I fully agree that we need clarity from NWBO on your points 2 & 3, though I think that news of at least the first of 3 vax-l combination trials is more important and more impactful than your number 1. I can't honestly say it bothers me: the long silence created the opportunity to own a heck of lot more shares than I had ever imagined owning. Which I bought because I strongly believe news will be forthcoming and multiple important news releases by the end of September if not in August, possibly as early as next week.
Direct is the farthest away from FDA approval and what NWBO really needs to turn around the pps crash in a hurry is to convince the market that the ph 3 trial is progressing and nearing data readout and/or that some sort of approval for combination treatment can get approved without a years long series of trials. I think the naysayers will be very surprised to see one or both of those in the near term. Either one will probably bring a lot of new money from new investors as well as from cautious current investors. Maybe even more cash from Woodford as he clearly has not given up and would be very happy to hear such positive news.